Last reviewed · How we verify
U87 autologous CAR T-cell — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
U87 autologous CAR T-cell (U87 autologous CAR T-cell) — Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| U87 autologous CAR T-cell TARGET | U87 autologous CAR T-cell | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- U87 autologous CAR T-cell CI watch — RSS
- U87 autologous CAR T-cell CI watch — Atom
- U87 autologous CAR T-cell CI watch — JSON
- U87 autologous CAR T-cell alone — RSS
Cite this brief
Drug Landscape (2026). U87 autologous CAR T-cell — Competitive Intelligence Brief. https://druglandscape.com/ci/u87-autologous-car-t-cell. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab